VectorXcellerator Programme: Fully funded feasibility studies to support early-stage cell and gene therapy programmes

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Home – News

Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease

January 3, 2022 | News